Use of transplatin to prevent hearing loss
Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.
1. A method of treating or preventing ototoxic effects of an ototoxic agent in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of transplatin.
2. The method of claim 1 , wherein the method comprises administering the transplatin to the subject before exposure of the subject to the ototoxic agent.
3. The method of claim 1 , wherein the method comprises administering the transplatin to the subject during exposure of the subject to the ototoxic agent.
4. The method of claim 1 , wherein the method comprises administering the transplatin to the subject after exposure of the subject to the ototoxic agent.
5. The method of claim 1 , wherein the transplatin is administered via intraperitoneal injection or trans-tympanic injection.
6. The method of claim 1 , wherein the transplatin is administered via oral administration.
7. The method of claim 1 , wherein the ototoxic agent is selected from a platinum-based chemotherapy agent, radiation, Meniere's disease, noise, and an aminoglycoside.
8. The method of claim 7 , wherein the ototoxic agent is noise.
9. The method of claim 7 , wherein the ototoxic agent is an aminoglycoside.
10. The method of claim 7 , wherein the ototoxic agent is a platinum-based chemotherapy agent.
11. The method of claim 2 , wherein the ototoxic agent is selected from a platinum-based chemotherapy agent, radiation, Meniere's disease, noise, and an aminoglycoside.
12. The method of claim 3 , wherein the ototoxic agent is selected from a platinum-based chemotherapy agent, radiation, Meniere's disease, noise, and an aminoglycoside.
13. The method of claim 4 , wherein the ototoxic agent is selected from a platinum-based chemotherapy agent, radiation, Meniere's disease, noise, and an aminoglycoside.
14. The method of claim 1 , wherein the amount of transplatin is between about 0.1 mg/kg and about 50 mg/kg.
15. The method of claim 1 , wherein the ototoxic agent is another therapeutic agent and the transplatin is administered simultaneously with the other therapeutic agent.
16. The method of claim 1 , wherein the ototoxic agent is another therapeutic agent and the transplatin is administered within about 24 hours before administration of the other therapeutic agent.
17. The method of claim 1 , wherein the ototoxic agent is another therapeutic agent and the transplatin is administered within about 24 hours after administration of the other therapeutic agent.
18. The method of claim 16 , wherein the ototoxic agent is another therapeutic agent and the transplatin is administered within about 1 to about 6 hours before administration of the other therapeutic agent.
19. The method of claim 17 , wherein the ototoxic agent is another therapeutic agent and the transplatin is administered within about 1 to about 6 hours after administration of the other therapeutic agent.